company background image
H7T1 logo

HUTCHMED (China) DB:H7T1 Stock Report

Last Price

€15.30

Market Cap

€2.6b

7D

-3.8%

1Y

18.6%

Updated

24 Mar, 2024

Data

Company Financials +

H7T1 Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.

H7T1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance3/6
Financial Health5/6
Dividends0/6

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£15.30
52 Week HighUK£19.10
52 Week LowUK£9.65
Beta0.66
1 Month Change7.75%
3 Month Change0.66%
1 Year Change18.60%
3 Year Change-32.89%
5 Year Change-43.85%
Change since IPO-33.54%

Recent News & Updates

Recent updates

Shareholder Returns

H7T1DE PharmaceuticalsDE Market
7D-3.8%2.6%1.4%
1Y18.6%-24.2%7.5%

Return vs Industry: H7T1 exceeded the German Pharmaceuticals industry which returned -24.2% over the past year.

Return vs Market: H7T1 exceeded the German Market which returned 7.5% over the past year.

Price Volatility

Is H7T1's price volatile compared to industry and market?
H7T1 volatility
H7T1 Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: H7T1's share price has been volatile over the past 3 months.

Volatility Over Time: H7T1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20001,988Wei-Guo Suhttps://www.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
H7T1 fundamental statistics
Market cap€2.61b
Earnings (TTM)€93.26m
Revenue (TTM)€775.48m

27.9x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
H7T1 income statement (TTM)
RevenueUS$838.00m
Cost of RevenueUS$686.45m
Gross ProfitUS$151.55m
Other ExpensesUS$50.77m
EarningsUS$100.78m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin18.08%
Net Profit Margin12.03%
Debt/Equity Ratio10.7%

How did H7T1 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.